Usefulness of autologous serum for ocular surface lesions with uncertain progression. A clinical and imaging evaluation

Objective: To determine the effectiveness of autologous serum rich in growth factors to repair ocular surface lesions which have uncertain progression with conventional treatment. Materials and methods: AForty-six (46) eyes with ocular surface disorders such as exposure keratopathy, keratopathy caus...

Descripción completa

Detalles Bibliográficos
Autores: Borobio, E, Hernández-Patiño, I, Rossani, G, López, E, Talavera, E, De la Cruz, J
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:Perú
Institución:Universidad de San Martín de Porres
Repositorio:Horizonte médico
Idioma:español
OAI Identifier:oai:horizontemedico.usmp.edu.pe:article/1367
Acceso en línea:https://horizontemedico.usmp.edu.pe/index.php/horizontemed/article/view/1367
Access Level:acceso abierto
Palabra clave:Serum
Intercellular signaling peptides and proteins
Platelet-rich plasma
Eye injuries
Suero
Factores de crecimiento
Plasma rico en plaquetas
Lesiones oculares
Descripción
Sumario:Objective: To determine the effectiveness of autologous serum rich in growth factors to repair ocular surface lesions which have uncertain progression with conventional treatment. Materials and methods: AForty-six (46) eyes with ocular surface disorders such as exposure keratopathy, keratopathy caused by dry eye syndrome, neurotrophic keratopathy and blunt eye injury were treated. The affected areas were the conjunctiva, cornea (epithelium, stroma) and sclera. Anatomical and functional evaluations were performed betweenMarch and December 2020 using Schirmer’s test, fluorescein eye stain and optical coherence tomography (OCT). Results: The symptoms improved in the following order: eye pain, foreign body sensation, blepharospasm, hyperemia and epiphora. Additionally, the lesions progressed favorably as follows: first, those of the conjunctiva and corneal epithelium; then, those of the corneal stroma; and, finally, those of the sclera. An average of 15 days was required for immediate ocular surface recovery and 21 days for late recovery. The lesions with total scleral thinning healed in about two months. Conclusions: The findings related to pain threshold, recovery time, scar tissue remodeling of the affected tissue and visual acuity improvement are promising and important. Using autologous serum rich in growth factors may be a therapeutic alternative for those lesions that are difficult to resolve with conventional treatment.